05.12.06
Genentech, Inc. has made two vice president appointments: Michael P. Miller to vice president, sales and marketing, HER Family; and David Schenkein, M.D., to vice president, clinical hematology/oncology. Mr. Miller is replacing John Orwin who was promoted to vice president, BioOncology.
Mr. Miller will be responsible for leading all sales and marketing activities for Herceptin and Tarceva and will report to Mr. Orwin. He joins the company from Connetics Corp., where he was senior vice president, chief commercial officer and led the commercial activities for the company's medical dermatology businesses. Mr. Miller has more than 25 years of pharmaceutical sales and marketing experience and has held various commercial leadership roles with Alza Corp., Vivus Corp. and Syntex Laboratories.
Mr. Schenkein will be responsible for leading the medical and scientific strategies for the Development BioOncology portfolio, as well as overseeing the BioOncology Clinical Science and Medical Science Liaison functions. Genentech's BioOncology marketed products include Avastin, Herceptin, Rituxan, and Tarceva. He will report to Hal Barron, M.D., senior vice president, development, and chief medical officer. He joins the company from Millennium Pharmaceuticals, where he held several executive leadership positions, including most recently, senior vice president of clinical research. Prior to his positions at Millennium, he spent 18 years in academic/clinical medicine. Additionally, Mr. Schenkein is an associate professor of Medicine at Tufts University School of Medicine.
Mr. Miller will be responsible for leading all sales and marketing activities for Herceptin and Tarceva and will report to Mr. Orwin. He joins the company from Connetics Corp., where he was senior vice president, chief commercial officer and led the commercial activities for the company's medical dermatology businesses. Mr. Miller has more than 25 years of pharmaceutical sales and marketing experience and has held various commercial leadership roles with Alza Corp., Vivus Corp. and Syntex Laboratories.
Mr. Schenkein will be responsible for leading the medical and scientific strategies for the Development BioOncology portfolio, as well as overseeing the BioOncology Clinical Science and Medical Science Liaison functions. Genentech's BioOncology marketed products include Avastin, Herceptin, Rituxan, and Tarceva. He will report to Hal Barron, M.D., senior vice president, development, and chief medical officer. He joins the company from Millennium Pharmaceuticals, where he held several executive leadership positions, including most recently, senior vice president of clinical research. Prior to his positions at Millennium, he spent 18 years in academic/clinical medicine. Additionally, Mr. Schenkein is an associate professor of Medicine at Tufts University School of Medicine.